Current partner codePEPTIDESDE
NCT03201419·Phase 2·INTERVENTIONAL

A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults

Status

Completed

Phase

Phase 2

Enrollment

302

Locations

72

Results

Posted

Publications

1

Study summary

What the protocol is testing.

The purpose of this trial was to investigate the efficacy, safety and tolerability of different oral doses of FE 201836, with desmopressin as a benchmark, during 12 weeks of treatment for nocturia due to nocturnal polyuria in adults

Interventions

Treatment arms and agents.

DRUG

FE 201836

Oral solution for daily intake

DRUG

Desmopressin

Desmopressin Orally Disintegrating Tablet (ODT)

DRUG

Placebo oral solution

Manufactured to mimic experimental drug

DRUG

Placebo ODT

Manufactured to mimic experimental drug

Timeline

From registration to results.

  1. First posted

    Jun 28, 2017

  2. Study start

    Jul 27, 2017

  3. Primary completion

    Oct 31, 2019

  4. Study completion

    Oct 31, 2019

  5. Results posted

    Dec 23, 2020

  6. Registry updated

    Mar 2, 2022

Outcomes

What the study measures.

Primary outcomes

Change From Baseline in Aggregated Mean Number of Nocturnal Voids During 12 Weeks of Treatment

Time frame · Baseline, during 12 weeks of treatment

Nocturnal voids were defined as voids occuring from 5 minutes after bedtime until rising in the morning. The number of nocturnal voids at each visit was calculated as the average over the 3 consecutive 24 hour periods just prior to the respective visit. The visit-specific means were aggregated into a mean of current and preceding visits. Level estimated for baseline value of mean number of nocturnal voids equal to 2, and 95% credibility interval (2.5 and 97.5 percentiles of the posterior distribution) instead of confidence interval are presented in this endpoint.

Secondary outcomes

Change From Baseline in Mean Number of Nocturnal Voids at Week 1

Time frame · Baseline, Week 1

Nocturnal voids were defined as voids occuring from 5 minutes after bedtime until rising in the morning. The number of nocturnal voids at each visit was calculated as the average over the 3 consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in nocturnal voids are estimated using a baseline value of 2. MMRM=Mixed Model for Repeated Measurements. For all visit-specific results, the tables present the number of subjects with an observation of the endpoints in question at the specific visit. All secondary analyses are performed using the observed-case approach based on repeated measurements for all subjects in the ITT-RT population. That is, these secondary analyses are based on all subjects with at least one non-missing post-baseline observation (with a baseline value if relevant).

Change From Baseline in Mean Number of Nocturnal Voids at Week 4

Time frame · Baseline, Week 4

Nocturnal voids were defined as voids occuring from 5 minutes after bedtime until rising in the morning. The number of nocturnal voids at each visit was calculated as the average over the 3 consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in nocturnal voids are estimated using a baseline value of 2.

Change From Baseline in Mean Number of Nocturnal Voids at Week 8

Time frame · Baseline, Week 8

Nocturnal voids were defined as voids occuring from 5 minutes after bedtime until rising in the morning. The number of nocturnal voids at each visit was calculated as the average over the 3 consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in nocturnal voids are estimated using a baseline value of 2.

Change From Baseline in Mean Number of Nocturnal Voids at Week 12

Time frame · Baseline, Week 12

Nocturnal voids were defined as voids occuring from 5 minutes after bedtime until rising in the morning. The number of nocturnal voids at each visit was calculated as the average over the 3 consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in nocturnal voids are estimated using a baseline value of 2.

Responder Rate in Nocturnal Voids at Week 1

Time frame · Week 1

Defined as 50% reduction in nocturnal voids from baseline. Adjusted visit-specific estimated odds of at least 50% in the reduction mean number of nocturnal voids are estimated using a baseline value of 2. The estimated odd equals the probability of response divided by the probability of non-response; these odds may vary between 0 and infinity. For example, if the probability of responding is 80%, the odd of responding is 4, as it is 4 times more likely to respond (80%) then it is not to respond (20%).

Responder Rate in Nocturnal Voids at Week 4

Time frame · Week 4

Defined as 50% reduction in nocturnal voids from baseline. Adjusted visit-specific estimated odds of at least 50% reduction in the mean number of nocturnal voids are estimated using a baseline value of 2. The estimated odd equals the probability of response divided by the probability of non-response; these odds may vary between 0 and infinity. For example, if the probability of responding is 80%, the odd of responding is 4, as it is 4 times more likely to respond (80%) then it is not to respond (20%).

Responder Rate in Nocturnal Voids at Week 8

Time frame · Week 8

Defined as 50% reduction in nocturnal voids from baseline. Adjusted visit-specific estimated odds of at least 50% reduction in the mean number of nocturnal voids are estimated using a baseline value of 2. The estimated odd equals the probability of response divided by the probability of non-response; these odds may vary between 0 and infinity. For example, if the probability of responding is 80%, the odd of responding is 4, as it is 4 times more likely to respond (80%) then it is not to respond (20%).

Responder Rate in Nocturnal Voids at Week 12

Time frame · Week 12

Defined as 50% reduction in nocturnal voids from baseline. Adjusted visit-specific estimated odds of at least 50% reduction in the mean number of nocturnal voids are estimated using a baseline value of 2. The estimated odd equals the probability of response divided by the probability of non-response; these odds may vary between 0 and infinity. For example, if the probability of responding is 80%, the odd of responding is 4, as it is 4 times more likely to respond (80%) then it is not to respond (20%).

Responder Rate in Nocturnal Voids During 12 Weeks of Treatment

Time frame · During 12 weeks of treatment

Defined as 50% reduction in nocturnal voids from baseline. Estimated odds of at least 50% reduction in the aggregated mean number of nocturnal voids for a subject with 2 nocturnal voids at baseline are presented in this endpoint. The 95% credibility interval (2.5 and 97.5 percentiles of the posterior distribution) instead of confidence interval is presented for this endpoint. The estimated odd equals the probability of response divided by the probability of non-response; these odds may vary between 0 and infinity. For example, if the probability of responding is 80%, the odd of responding is 4, as it is 4 times more likely to respond (80%) then it is not to respond (20%).

Change From Baseline in Mean NI Diary Total Score at Week 1

Time frame · Baseline, Week 1

The NI Diary is a 12-item questionnaire with 11 core items (Q1-Q11) and an overall quality of life (QoL) impact question (Q12). The NI Diary Total Scores are calculated by summing the 11 core items.Responses are scored from 0 to 4 (lowest t o highest impact). The NI Diary Total is standardized from 0 to 100 (lowest to highest impact). The score at each visit was calculated as the average over the three consecutive 24 hour periods just prior to the respective visit. Adjusted visit-specific mean changes from baseline in NI Diary Total Score are estimated using a baseline value of 40.

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
Not reported
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * Adults ≥18 years of age (at the time of written consent) * Medical history of, or subject reported nocturia symptoms during the 6 months prior to Visit 1 * ≥2 nocturnal voids (an average over 3 days) as documented in the 3-day e-Diary prior to Visit 2 * The largest single voided volume must be ≥200 mL (at least 1 void ≥200 mL) as documented in the 3-day e-Diary prior to Visit 2 * Nocturnal polyuria, defined as Nocturnal Polyuria index \>33%, a ratio of Nocturnal Urine Volume in excess of 33% of total daily (24-hour) urine volume as documented in the 3-day e-Diary prior to Visit 2 * ≥20% decrease in the nocturnal diuresis rate (mL/min) (that was recorded at Visit 2) as documented in the 3-day e-Diary prior to Visit 3 Exclusion Criteria: * Current diagnosis of Obstructive Sleep Apnoea (OSA) * Restless Legs Syndrome (RLS) * Bladder Outlet Obstruction (BOO) or urine flow \<5 mL/s, as confirmed by uroflowmetry upon suspicion during screening prior to Visit 2 * Urinary incontinence defined as an average of \>1 episode/day in the 3-day e-Diary prior to Visit 2 (occasional urge incontinence during daytime or at night on the way to void is not necessarily exclusionary) * Any pelvic or lower urinary tract surgery and/or radio therapy or previous pelvic irradiation within the past 6 months prior to Visit 1. Including e.g., transurethral resection for Bladder Outlet Obstruction or Benign Prostatic Hyperplasia, hysterectomy or female incontinence procedures * Genito-urinary tract pathology that can in the investigator's opinion be responsible for urgency or urinary incontinence e.g., symptomatic or recurrent urinary tract infections, interstitial cystitis, bladder-related pain, chronic pelvic pain syndrome, or stone in the bladder or urethra causing symptoms * A history of cancer with the last date of disease activity/presence of malignancy within the last 12 months prior to Visit 1, except for adequately treated basal cell carcinoma of the skin * History of any neurological disease affecting bladder function or muscle strength (e.g., Multiple Sclerosis, Parkinson's, spinal cord injury, spina bifida) * Habitual (fluid intake \>3L per day) or psychogenic polydipsia * Uncontrolled hypertension, as judged by the investigator * Uncontrolled diabetes mellitus, as judged by the investigator * Central or nephrogenic diabetes insipidus * Known history of Syndrome of Inappropriate Antidiuretic Hormone (SIADH) secretion * History of gastric retention * Suspicion or evidence of congestive heart failure, (New York Heart Association (NYHA) class II, III, IV) * Hyponatraemia: * Serum sodium level \<135 mmol/L at Visit 1(re-tested, with results available within 7 days) * Serum sodium level \<130 mmol/L at Visit 3 (re-tested, with results available within 7 days) * Use of any prohibited therapy listed below: * Current or former (within 3 months prior to screening) treatment with any other investigational medicinal product (IMP) * Unstable electrostimulation or behavioural bladder training program less than 3 months prior to screening (stable electrostimulation or behavioural bladder training program started at least 3 months before screening are acceptable) * Thiazide diuretics * Antiarrhythmic agents * V2-receptor antagonists/agonists (e.g., vaptans/desmopressin, vasopressin) * Loperamide * Botulinum toxin (cosmetic non-urological use is acceptable) * Valproate

Study locations

72 registered sites.

Belgium · Canada · Czechia · Germany · Hungary · Poland · United States. Showing up to 24 locations stored in the fast local snapshot.

Achieve Clinical Research, LLC

Birmingham, Alabama, United States

Coastal Clinical Research, an AMR company

Mobile, Alabama, United States

Clinical Trials Research

Lincoln, California, United States

Tri Valley Urology Medical Group

Murrieta, California, United States

San Diego Clinical Trials

San Diego, California, United States

Advanced Rx Clinical Research Group, Inc.

Westminster, California, United States

Downtown Women's Health Care

Denver, Colorado, United States

Genitourinary Surgical Consultants, P.C.

Denver, Colorado, United States

South Florida Medical Research

Aventura, Florida, United States

Women's Medical Research Group, LLC

Clearwater, Florida, United States

Tampa Bay Medical Research, Inc.

Clearwater, Florida, United States

Clinical Research of South Florida

Coral Gables, Florida, United States

Avail Clinical Research, LLC

DeLand, Florida, United States

Finlay Medical Research Corp

Greenacres City, Florida, United States

Pharmax Research Clinic

Miami, Florida, United States

Doctors Research Institute Corporation

Miami, Florida, United States

Sanitas Research

Miami, Florida, United States

Bayside Clinical Research LLC

New Port Richey, Florida, United States

Pines Care Research Center, Inc

Pembroke Pines, Florida, United States

Clinical Research Center of Florida

Pompano Beach, Florida, United States

Meridien Research, Inc.

St. Petersburg, Florida, United States

American Health Network of Indiana, LLC

Avon, Indiana, United States

American Health Network of Indiana, LLC

Greenfield, Indiana, United States

Bay State Clinical Trials, Inc.

Watertown, Massachusetts, United States

Related trials

More studies on Desmopressin.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.